SLC5A2 and plasma cell myeloma: Indeed, a recent study of diabetics with multiple myeloma taking SGLT2 inhibitors, 42.4% of patients discontinued SGLT2 inhibitor use over a period of 15 months, with 21.4% of discontinuations being due to an increase in serum creatinine.14